The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Colorectal Neoplasms
/ complications
Combined Modality Therapy
Cytoreduction Surgical Procedures
/ adverse effects
Female
Humans
Hyperthermia, Induced
Longitudinal Studies
Male
Middle Aged
Morbidity
Peritoneal Neoplasms
/ complications
Prognosis
Sarcopenia
/ etiology
Survival Rate
Colorectal cancer
HIPEC
Long-term outcomes
Peritoneal carcinomatosis
Peritoneal metastases
Sarcopenia
Journal
Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
27
01
2019
accepted:
05
02
2020
pubmed:
23
2
2020
medline:
28
4
2021
entrez:
22
2
2020
Statut:
ppublish
Résumé
The aim of this study was to evaluate the prognostic value of preoperative sarcopenia with regard to postoperative morbidity and long-term survival in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). A longitudinal cohort study was conducted on patients with peritoneal metastases of colorectal origin treated with CRS-HIPEC between 2008 and 2018. Data on patient demographics, body mass index, operative characteristics, perioperative morbidity and survivorship status and oncological follow-up were obtained from the hospital registry. Sarcopenia was assessed using preoperative computed tomography (CT) findings. Sixty-five patients [mean (SD) age: 54.4 (13.4) years, 64.6% females] were included in the study. Sarcopenia was evident in 30.8% of patients, while mortality rate was 66.2% with median survival time of 33.6 months. Presence of sarcopenia was associated with older age (59.6 (9.2) vs. 52.1 (14.4) years, p = 0.038), higher likelihood of morbidity (70.0% vs. 35.6%, p = 0.015) and mortality (90.0% vs. 55.6%, p = 0.010) and shorter survival time (17.7 vs. 37.9 months, p = 0.005). Cox regression analysis revealed that the presence of sarcopenia (HR 2.245, 95% CI 0.996-5.067, p = 0.050) was a significant predictor of increased likelihood of mortality. Preoperative sarcopenia is an independent prognostic factor of postoperative morbidity and shorter survival in CRC peritoneal metastasis patients treated with CRS-HIPEC. Our findings support the importance of preoperative screening for sarcopenia as part of preoperative risk assessment for better selection of CRS-HIPEC candidates or treatment modifications in CRC patients with peritoneal metastasis.
Sections du résumé
BACKGROUND
The aim of this study was to evaluate the prognostic value of preoperative sarcopenia with regard to postoperative morbidity and long-term survival in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
METHODS
A longitudinal cohort study was conducted on patients with peritoneal metastases of colorectal origin treated with CRS-HIPEC between 2008 and 2018. Data on patient demographics, body mass index, operative characteristics, perioperative morbidity and survivorship status and oncological follow-up were obtained from the hospital registry. Sarcopenia was assessed using preoperative computed tomography (CT) findings.
RESULTS
Sixty-five patients [mean (SD) age: 54.4 (13.4) years, 64.6% females] were included in the study. Sarcopenia was evident in 30.8% of patients, while mortality rate was 66.2% with median survival time of 33.6 months. Presence of sarcopenia was associated with older age (59.6 (9.2) vs. 52.1 (14.4) years, p = 0.038), higher likelihood of morbidity (70.0% vs. 35.6%, p = 0.015) and mortality (90.0% vs. 55.6%, p = 0.010) and shorter survival time (17.7 vs. 37.9 months, p = 0.005). Cox regression analysis revealed that the presence of sarcopenia (HR 2.245, 95% CI 0.996-5.067, p = 0.050) was a significant predictor of increased likelihood of mortality.
CONCLUSIONS
Preoperative sarcopenia is an independent prognostic factor of postoperative morbidity and shorter survival in CRC peritoneal metastasis patients treated with CRS-HIPEC. Our findings support the importance of preoperative screening for sarcopenia as part of preoperative risk assessment for better selection of CRS-HIPEC candidates or treatment modifications in CRC patients with peritoneal metastasis.
Identifiants
pubmed: 32080800
doi: 10.1007/s10151-020-02159-z
pii: 10.1007/s10151-020-02159-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-308Références
Ann Surg Oncol. 2014 Jun;21(6):1792-800
pubmed: 24337648
J Clin Oncol. 2009 Feb 10;27(5):681-5
pubmed: 19103728
Dis Colon Rectum. 2014 Jul;57(7):858-68
pubmed: 24901687
J Geriatr Oncol. 2015 Nov;6(6):442-5
pubmed: 26365898
Ann Surg. 2015 Feb;261(2):345-52
pubmed: 24651133
Ann Surg Oncol. 2015 Oct;22(11):3625-31
pubmed: 25672564
Clin Cancer Res. 2007 Jun 1;13(11):3264-8
pubmed: 17545532
Ann Surg Oncol. 2015 Aug;22(8):2663-8
pubmed: 25564158
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Oral Oncol. 2017 Aug;71:26-33
pubmed: 28688687
J Clin Oncol. 2010 Jan 1;28(1):63-8
pubmed: 19917863
Lancet Oncol. 2016 Dec;17(12):1709-1719
pubmed: 27743922
Ann Surg Oncol. 2015 Aug;22(8):2656-62
pubmed: 25515200
Int J Hyperthermia. 2018 Aug;34(5):589-594
pubmed: 28828897
Ann Surg. 2009 Jun;249(6):900-7
pubmed: 19474692
Br J Cancer. 2012 Sep 4;107(6):931-6
pubmed: 22871883
Cancer. 2000 Jan 15;88(2):358-63
pubmed: 10640968
J Clin Oncol. 2003 Oct 15;21(20):3737-43
pubmed: 14551293
Ann Surg Oncol. 2016 Nov;23(12):3891-3898
pubmed: 27352205
Ann Surg Oncol. 2009 Aug;16(8):2152-65
pubmed: 19434455
Eur J Surg Oncol. 2018 Nov;44(11):1818-1823
pubmed: 30143249
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
J Surg Oncol. 2016 Jun;113(7):796-803
pubmed: 27110915
Clin Nutr. 2016 Aug;35(4):924-7
pubmed: 26205321
ANZ J Surg. 2017 Sep;87(9):665-670
pubmed: 28664645
HPB (Oxford). 2015 May;17(5):438-46
pubmed: 25512239
Ann Surg. 2006 Feb;243(2):212-22
pubmed: 16432354
Br J Surg. 2002 Dec;89(12):1545-50
pubmed: 12445064
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Eur Radiol. 2014 May;24(5):998-1005
pubmed: 24535076
Eur J Surg Oncol. 2017 Jun;43(6):1028-1039
pubmed: 28029523
Clin Nutr. 2018 Aug;37(4):1101-1113
pubmed: 28734552